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Abstract  
The impact of sex hormones on anticancer immunity deserves attention due to the 
importance of the immune system in cancer therapy and the recognition of sex 
differences in immunity. Cancer is ultimately the result of failed immune surveillance 
and diverging effects of male and female sex hormones on anticancer immunity could 
contribute to the higher cancer incidence and poorer outcome in men. Estrogens and 
androgens affect the number and function of immune cells, an effect that depends on 
cell type, tumor microenvironment, and the age and reproductive status of the 
individual. Despite the recent progress in immunooncology our current understanding 
of the interplay between sex hormones and anticancer immune responses is in its 
infancy. In this review we will focus on the impact of sex hormones on anticancer 
immunity and immunotherapy. We will discuss the potential role of the changing 
hormone levels in anticancer immunity during aging and in the context of 
postmenopausal hormone therapies and oral contraception. We will review emerging 
data on sex differences in PD-L1 expression and the efficacy of immune checkpoint 
inhibitors and consider ongoing clinical trials evaluating the potential impact of 
hormone deprivation therapies to increase response to immune checkpoint inhibitors 
in breast and prostate cancer. Lastly, we will point to areas of future research.  
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Introduction  
 Sex differences in cancer susceptibility and survival are well documented. 
Worldwide, men have a higher risk and mortality than women across various cancer 
types and races, with a few notable exceptions such as thyroid and gallbladder cancer 
[1]. Obvious differences between males and females are sex chromosomes and sex 
hormones. Both influence self-renewal of target stem cell populations, the tumor 
microenvironment and systemic determinants of carcinogenesis such as cell 
metabolism and the immune system [2]. 
A great achievement in oncology in the last years was the recognition of the 
role of the immune system in cancer development, with the introduction of 
immunotherapy for a variety of cancer types such as melanoma, lung and urinary tract 
cancers [3]. It is accepted that cancer development is the result of failed immune 
surveillance as illustrated by animal models [4] and the increased cancer risk of 
immunosuppressed patients, as a consequence of organ transplant rejection 
prevention [5] or HIV infection [6]. Tumors showing a strong immune cell infiltration 
(“inflamed”) elicit an innate immune response but escape cell killing by cytotoxic T 
cells probably through immunosuppressive pathways activated by cancer cells. In 
contrast, in "immune-excluded” tumors, which also contain abundant immune cells, 
the development of an effective antitumor immune response is blocked by the 
retention of immune cells in the tumor stroma , while tumors characterized by a paucity 
of T cells (“immune desert”) do not activate the innate immune system in the first place, 
corresponding to a state of immune exclusion [7].  
Innate and adaptive immune responses are affected by both chromosomal and 
hormonal factors and differ between men and women [8]. Women have overall 
stronger immune responses, as shown by the higher incidence of autoimmune 
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diseases in women and data on vaccine and infection responses [8]. The sex 
hormones estrogen, progesterone and testosterone regulate a variety of cellular 
functions in both reproductive and non-reproductive tissues, which are yet 
insufficiently studied [2]. Nearly all immune cells express receptors for these hormones 
[9-13] and many immune related genes possess androgen (AR) and estrogen receptor 
(ER) responsive elements in their promoters, which may underlie the sex differences 
in immune responses [14]. These can depend on specific immune cell types and their 
location as well as hormone levels and density and distribution of their receptors. In 
fact, the same sex hormones can have both immune stimulatory and inhibitory effects 
as a function of dose(s) and time(s) [15]. A comprehensive review of the sex 
differences in immunity is beyond the scope of this paper, for a recent review on the 
hormonal effects on immune cells see [8]. 
Estrogens and androgens have been shown to exert opposite effects on B- and T- 
cells, macrophages, neutrophils and natural killer (NK) cells [10, 16-18]. However, it is 
important to stress that these differences have been mostly studied in mouse models, 
and whether or not they apply directly to human cells and especially to cancer patients 
is currently unknown. Additionally, an essential question to be addressed is how the 
throughout lifetime changing levels of estrogens and androgens in humans affect 
various immune cell types and ultimately the clinical behavior and treatment outcome 
of various cancers.  
 
Effect of sex hormones on immunity as a function of age 
 The exponential increase of cancer incidence with age can be attributed to 
various factors including the accumulation of genetic mutations and changes in the 
immune system. Specifically, aging exerts a significant impact on estrogen and 
androgen levels and signalling, differently between males and females and is itself 
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controlled by these hormones. Aging is associated with a rapid decrease in estrogen 
levels in women and a rather progressive decline in androgen concentrations in men 
[19]. Women synthesize androgens and their precursors (e.g. DHEAs) in the adrenal 
glands and ovaries [20] with premenopausal total testosterone levels corresponding 
to one-twentieth of those found in adult men [21] [22]. In the absence of assays 
allowing accurate measurement of the low levels of testosterone in women, the 
occurrence of androgen deficiency in post-menopausal women is debated [23]. In 
men, testosterone is reduced to dihydrotestosterone (DHT), which binds more avidly 
to the AR and is converted into estradiol by the cytochrome P450 aromatase present 
in adipose tissue, skin, bone and other organs [24]. Some studies [25], but not others 
[26], have suggested that estradiol levels decrease in parallel with testosterone in 
aging men (Table 1). In general, considerable interindividual heterogeneity renders 
the establishment of age-dependent reference ranges for sex hormones in men and 
women challenging [25]. Additionally, an individual’s true sex hormone status during 
lifetime is most likely determined by the combination of serum estradiol, testosterone 
and dihydrotestosterone levels as well as body mass index (BMI) and sex hormone 
receptor activity [27]. 
The accelerated rate of aging in men is correlated with a more pronounced decline in 
total T and B cell numbers and a larger increase in senescent CD8 T effector memory 
cells compared to aging women [28, 29]. In women, menopause is associated with an 
increase in pro-inflammatory IL-1β, IL6 and TNFα levels and a reduction in the anti-
inflammatory IFNγ levels. Monocytes and NK cells of aged women exhibit a pro-
inflammatory phenotype and more robust cytotoxic activity, respectively, compared to 
those of aged men. For a recent comprehensive review on the effect of sex hormones 
on aging and immunity see [30].  
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Aging induces a state of chronic low-grade inflammation that has been named as 
“inflammaging” and which is believed to be the consequence of various inflammatory 
cytokines secreted by the increasing number of senescent cells in several organs. 
Multiple stimuli such as oxidative stress, DNA damage, telomere dysfunction or 
environmental carcinogens can induce the senescence-associated secretory 
phenotype (SASP) which has been proposed to be the main origin of inflammaging in 
both aging and age-related diseases such cancer [31]. Although not reported, it is 
likely that the physiological decline in sex hormones during aging plays a role in 
cellular senescence.  
Therapeutic increase of sex hormone levels and cancer immunity  
The association between cancer risk and changes in sex hormone levels during 
aging implies that the effect of hormonal therapies should be further investigated. In 
postmenopausal women, hormone replacement therapies (HRT) are associated with 
an increased cancer risk of hormone-responsive tissues such as breast [32], 
endometrium [33] and ovaries [34]. The response of different tissues and cell types to 
HRT might depend on the presence of concomitant risk factors such as obesity and 
the individual genetic background. It was reported that HRT partially reverses the 
impact of aging on immunity by increasing B and T cell counts [35], and by decreasing 
levels of pro-inflammatory cytokines - TNFα and IL-6-  in postmenopausal women [36].  
 Likewise, various forms of hormonal contraception (HC), mostly administered 
as oral estrogen-progestin combinations, correlate with increased breast cancer risk 
(analysis of data from 1.8 million women) [37]. This occurs despite increased numbers 
of B and T cells [38], suggesting that the direct growth stimulating effect of sex 
hormones on the epithelium of reproductive tissues might overweigh effects on the 
immune system. Experimental evidence for this hypothesis is however lacking and 
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differences in types, doses and duration of HC might also alter its impact on immune 
responses. Long-term oral HC is also correlated with increased risk of 
adenocarcinoma in situ of the cervix [39]. While infection with human papillomavirus 
(HPV) and immunosuppression are established causes of cervix cancer, reports on 
the association between long-term HC use and impaired virus clearance resulting in 
persistent HPV infections are inconsistent. It is possible that only some oncogenic 
HPV types, such as HPV16, are associated with HC exposure [40]. Given that most 
women will be infected with HPV during their lifetime, a possible negative effect of HC 
on immune responses against these viruses needs to be evaluated.  
In contrast, HC use is associated with a significant reduction of ovarian cancer risk 
(data from forty-five epidemiological studies) [41] even in BRCA 1 or 2 gene mutation 
carriers [42]. Also, a decreased risk for colorectal and endometrial cancer has been 
found in HC users [43]. The mechanisms behind these opposing effects of 
postmenopausal HRT and HC on ovarian and endometrial cancer risk are currently 
unclear and it needs to be determined how the interference with physiological sex 
hormone levels and cycles can selectively modulate cancer risk of different organs. 
It has not been reported yet whether testosterone replacement therapy 
influences immune responses in aged men.  
 
Sex differences in PD-L1 expression and response to immune therapies   
The duration and magnitude of immune responses are tightly controlled by 
inhibitory immune checkpoints to avoid autoimmunity. These protective signaling 
pathways are often hijacked by tumors to escape immune surveillance [3]. The 
currently best characterized immune checkpoints are CTLA-4, which is constitutively 
expressed in regulatory T cells and upregulated upon activation of naïve T  
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cells; PD-1, which is found in T cells, B cells and natural killer (NK) cells; and the PD-
L1, a PD-1 ligand expressed in antigen presenting cells and cancer cells [44]. Some 
animal studies and emerging clinical evidence suggest a role for estrogens in 
upregulation of PD-1 and PD-L1 expression [45, 46], and for sex differences in the 
response to immune checkpoint inhibitors [47-49].  
Female sex has been suggested as a negative predictive factor for response of 
melanoma patients to anti-PD1-therapy [47]. One explanation for this finding might be 
the paucity of partially exhausted PD-1high/CTLA-4–positive CD8 cells associated with 
response to combined checkpoint inhibition in women [50], while an hormone-
mediated mechanism might also be important. However, in absence of pre-planned 
subgroup analyses according to sex from large clinical trials or pooled analyses based 
on individual patient data no definitive conclusions can be drawn yet.   
Robust predictive biomarkers, beyond high PD-L1 expression, high tumor 
mutational burden or the presence of tumor infiltrating lymphocytes (TILs) [51], are 
lacking. The gut microbiome is emerging as a modulator of response to immune 
checkpoint inhibitors. In a recent study of melanoma patients undergoing anti-PD1 
therapy, significant differences were found in the diversity and composition of the gut 
microbiome of responders compared to non-responders. Patients with the most 
diverse microbiome were more likely to respond to immunotherapy, while antibiotic 
therapy was predictive of resistance to anti-PD1 blockade. Fecal transplants from 
responders to germ-free or antibiotics treated mice resulted in increased anti-tumor 
immunity with reduced tumor growth [52] [53]. Studies in mice and human have shown 
that the gut microbiome is affected by various factors including sex, age, diet and 
obesity and itself also contributes substantially to sex differences in immunity [54, 55]. 
 10 
Although very likely, the crosstalk among sex hormones, microbiome composition and 
immune system in men and women has as yet to be studied.  
Also, obesity was positively correlated with overall survival in men with metastatic 
melanoma treated with immune checkpoint inhibitors while no correlation was found 
in women [56]. Although this kind of retrospective analysis has several limitations, 
these findings are hypothesis-generating and insinuate possible biological and/or 
hormonal differences.   
A comparison of the PD-1/PD-L1 expression in male versus female cancer 
patients of different ages as well as in patients undergoing hormonal therapies is 
largely missing. Some small studies report an association between elevated PD-L1 
expression and male sex [57] [58]. Since in current clinical practice PD-L1 positivity is 
mostly correlated with poor prognosis but predictive of response to immune checkpoint 
inhibitors [51], sex differences in PD-L1 expression could partially account for the 
overall poorer prognosis of men and better response to immune checkpoint inhibitors. 
In fact, a recent meta-analysis of clinical trials of immune checkpoint inhibitors for 
various indications reported a significant survival advantage for men treated with anti-
CTLA4 or anti-PD1 therapies compared to women [49]. Even though these results are 
not based on individual patient data and the majority of the clinical trials are 
underpowered to detect clinically relevant sex differences in outcome and rarely report 
efficacy and toxicity according to sex, these results are thought-provoking. They hint 
at possible sex differences in the predominant immune escape mechanisms of 
cancers arising in men and women and indicate that the hormonal milieu might affect 
therapy response (Figure 1).  
A plethora of checkpoints attenuating (LAG3, TIM3) or stimulating (OX40, 
CD27) immune responses, respectively, have been identified and are being 
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investigated as potential targets for immune therapies [59]. In view of the recent data, 
the possibility that using different immunotherapy approaches in men and women 
could improve response rates merits further investigation. In addition, while 
immunotherapy induced endocrinopathies are well documented, a possible impact on 
ovarian and testicular function has not been explored [60].   
 
Sex hormone deprivation therapies as co-adjuvants for immune therapies 
Inhibition of estrogen or androgen signaling is a cornerstone in the treatment of 
hormone-dependent tumors such as breast and prostate cancers. Since these 
therapies inhibit cancer cells, it is difficult to evaluate their immunomodulatory effects.  
Anti-estrogen therapies 
Tamoxifen and fulvestrant, a selective modulator and degrader of estrogen 
receptor, respectively, affect antigen presentation. In vitro and mouse experiments 
have shown a 2-3 fold increased expression of hormonally regulated tumor antigens 
such as α-Lactalbumin in ER-positive breast cancer cells treated with tamoxifen or 
fulvestrant [61]. This upregulation in antigen expression is correlated with increased 
anticancer immunity given that tumor-bearing mice respond to treatment with antigen-
specific lymphocyte transfer [61]. Tamoxifen stimulates neutrophil activity in vitro and 
in vivo through modulation of sphingolipid biosynthesis [62] and was shown to diminish 
the number of immunosuppressive myeloid derived suppressor cells (MDSCs) and 
increase the population of effector and cytotoxic T cells that infiltrated the tumor in a 
mouse model of ERα negative ovarian cancer [63]. 
The aromatase inhibitor letrozole significantly reduces the number of Tregs in 
human breast cancer tissue, which is correlated with therapy response [64].  
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These results suggest a potential role for anti-estrogen therapies in enhancing the 
efficacy of immunotherapies and early phase clinical trials are testing this hypothesis 
in hormone-receptor positive breast cancers (Table 2). 
Androgen deprivation therapies 
Similar immune stimulatory effects were reported with the suppression of 
androgen signaling [65, 66]. Immune cells isolated from men with androgen 
deficiencies produce more pro-inflammatory cytokines such as IL-1β, IL-2 and TNFα 
when stimulated with lipopolysaccharides (LPS) [67], which is reverted upon androgen 
replacement [67] [68] [69]. Androgen deprivation therapy (ADT), standard of care in 
prostate cancer, induces expansion of naïve T cells and increases T cell responses, 
an effect observed from 1-24 months [70]. Histologically, ADT is associated with a 
strong T cell and macrophage infiltration into the prostate after 1 week of treatment 
[71, 72]. Several studies demonstrated that ADT enhances susceptibility of AR-
overexpressing prostate cancer cells to immune-mediated T cell killing through 
improved immune recognition [73] [74]. Emerging clinical data also reveals that ADT 
enhances the efficacy of various immunotherapies including immune checkpoint 
blockade [75] and cancer vaccines such as spileucel T [76] and Prostvac [77].  
Clinical trials combining ADT with abiraterone acetate, which inhibits androgen 
synthesis in the adrenals, and enzalutamide, an AR ligand competitive antagonist with 
different immunotherapies are ongoing. These combination therapies might improve 
the rather poor response rate of prostate cancer patients to immune checkpoint 
inhibitors (Table 2).  
Although the optimal timing and duration of such therapies remain to be 
determined, animal experiments [78] and data from a phase II clinical trial [77] suggest 
 13 
that sequential therapy with administration of immunotherapy before AR antagonists 
rather than after or concomitant to ADT could improve therapeutic responses.   
 
Conclusions and areas of future research  
Despite the impressive achievements in the field of immunooncology, our 
understanding of the interplay between sex hormones and anticancer immunity is 
lagging behind. The immune system of females and males evolves in a different 
hormonal environment resulting in distinct immune responses which vary with the 
aging related decline in sex hormones. At the same time, genetic factors such as 
localization of many immune related genes and the miRNAs implicated in their control 
on the X chromosome, are also likely to contribute to the observed sex disparities in 
immunity [79]. In addition to investigating the role of physiological sex hormone levels 
and their variation during aging in anticancer immunity, studying the immune system 
of individuals with pathological hormone levels or genetic mutations blocking or 
diminishing male sex differentiation of individuals with XY chromosomes and with or 
without functioning testicles (e.g. SRY, SOX 9 and AR mutations) could help dissecting 
the effect of sex hormones from that of sex chromosomes [80, 81]. 
Furthermore, elucidating the relationship between sex hormones, obesity, the 
gut microbiome and immune responses in men and women could improve our 
understanding of resistance mechanisms to immune checkpoint inhibitors and better 
select patients who might benefit from these costly therapies.  
While immune signals appear to play a role in the reactivation of disseminated 
tumor cells (DTCs) surviving in a “dormant” state in distant organs, the influence of 
sex hormones in this context is, however, currently unknown [82]. Since hormone-
responsive tumors such as ER-positive breast cancer and prostate cancer can relapse 
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after years or even decades of apparent remission, investigation of a possible 
association between changes of sex hormone levels during aging or pharmacological 
treatment and reawakening of DTCs is of great clinical interest (Figure 1).   
Various topics such as the impact of pregnancy on cancer relapse are still a 
matter of debate with controversial findings [83]. There is an unmet need to thoroughly 
characterize the immunological changes that occur during pregnancy and 
systematically collect data on pregnancy-associated cancers. Evidence-based 
recommendations regarding pregnancy are required to appropriately counsel the 
increasing population of cancer survivors in child-bearing age. 
Lastly, we need to revisit clinical trial design in immunooncology. The trend to 
empirically combine different immunotherapy approaches with or without standard 
therapies is increasingly questionable. This approach should be replaced by rational 
combination strategies based on a better understanding of the mechanism of action 
and the effects of sex chromosomes and hormones on immune responses. Also, the 
reporting of trial results should contain subgroup analyses according to sex and 
discuss whether the study was sufficiently powered to detect potentially relevant sex 
differences, the plausibility of the findings as well as their biological basis. A close 
collaboration between different institutions and data sharing could help advance the 
field of immunooncology.  
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 Age Men Women Ref 
Mean total Testosterone 
(ng/dl) 
25-54 469-553 23-45 [1-3]  
> 55 469-475 19-20 
Mean free Testosterone 
(ng/dl) 
25-54 9-12 0.3-0.7 [1-3] 
>55 7-8.3 0.3 
Mean DHEAS (μg/dl) 25-54 151-286  126-276 [2, 3] 
>55 114-137 65-87 
Mean Estradiol (pg/ml) 25-54 25.1-25.7 30-800 [4, 5]  
>55 /postmenopausal 25.7-29.7 <20 
Mean free Estradiol (pg/ml) 25-54 0.54-0.56 2.4-3.1 [4, 6] 
>55/ postmenopausal 0.46-0.53 <0.5 
 
Table 1 Differences in sex hormone levels in men and women during aging 
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Indication Drugs Phase Study ID Number of 
participants, Primary 
endpoints 
Study 
completion 
date 
ER+ HER2- BC Exemestane + Tremelimumab  
 
Exemestane + Durvalumab 
Phase 1 
 
Phase 2 
NCT02997995 
ULTIMATE 
N=240, pathological 
CR 
Sep 2020 
ER+ BC Letrozole + Pembrolizumab +Palbociclib Phase 2 NCT02778685 
 
N= 22, ORR Sep 2018 
HR+ HER2- BC Tamoxifen/Fulvestrant/Exemestane + 
Atezolizumab + Targeted therapies 
Phase 1/2 NCT03280563 
MORPHEUS 
N=111, ORR Oct 2022 
HR+ HER2- BC, 
premenopausal 
Exemestane+ Leuprolide (GnRH analog) + 
Pembrolizumab 
Phase 1/2 NCT02990845 
 
N=25, PFS Dec 2019 
HR+ IBC  Tamoxifen/Aromatase inhibitor/LHRH 
agonist (physician’s choice) 
+ Pembrolizumab 
Phase 2 NCT02971748 
 
N=37, DFS Jan 2020 
HR+ BC or TNBC Anti-estrogen + Pembrolizumab   
vs Pembrolizumab+ Doxorubicine 
Phase 2 NCT02648477 
 
N=56, Safety, ORR Sep 2018 
AR+ TNBC Pembrolizumab 
+ Enobosarm (Selective AR modulator) 
Phase 2 NCT02971761 
 
N=29, Safety, ORR Oct 2018 
mCRPC Enzalutamide + Atezolizumab  
vs Enzalutamide 
Phase 3 NCT03016312 
 
N=730, OS 
 
Jul 2022 
mCRPC Enzulatamide + Pembrolizumab Phase 2 NCT02312557 
 
N=58, PSA response Jan 2019 
mCRPC Enzalutamide + Pembrolizumab 
vs Pembrolizumab 
Phase 2 NCT02787005 
KEYNOTE 199 
N=370, ORR Mar 2020 
mCRPC Enzalutamide + PROSTVAC-F/V-TRICOM 
vs Enzalutamide 
Phase 2 NCT01867333 
 
N=57, TTP Jan 2019 
mCRPC Enzalutamide + Spileucel-T 
Concurrent vs sequential administration 
Phase 2 NCT01981122 
STRIDE 
N=52, T cell 
response  
NA 
mCRPC Abiraterone acetate (CYP17 inhibitor)+ 
Prednisone 
+ Ipilimumab 
Phase 1/2 NCT01688492 
 
N=57, PFS; safety Sep 2018 
CSPC Enzalutamide (AR antagonist) + 
PROSTVAC-F/V-TRICOM 
vs Enzalutamide 
Phase 2 NCT01875250 
 
N=38, Tumor growth Jan 2019 
CSPC, adjuvant or 
after recurrence 
Degarelix (GnRH antagonist)+ Ipilimumab Phase 2 NCT02020070 
 
N=16, PSA response Dec 2018 
Localized PC, 
neoadjuvant 
Degarelix+ Cyclophosphamide+GVAX 
vs Degarelix 
Phase 1/2 NCT01696877 
 
N=29, CD8+ T cell 
infiltration, adverse 
events 
May 2019 
 
Table 2 : Clinical trials combining anti-estrogen or androgen deprivation therapy with immunotherapies in breast and prostate 
cancer, respectively.  
ER+: Estrogen receptor positive, BC: breast cancer, HR+: hormone receptor positive, OS: overall survival, TTP: time to 
progression, CR: complete response, DFS: disease free survival, IBC: inflammatory breast cancer, TNBC: triple negative breast 
cancer, AR+: androgen receptor positive, mCRPC: metastatic castration resistant prostate cancer, CSPC: castration sensitive 
prostate cancer, PC: prostate cancer, NA: not available 
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Figure 1 Sex hormones, genetic and environmental factors contribute to sex 
differences in anticancer immunity.  
 
The crosstalk between sex hormone signalling and genetic and environmental factors 
affects sex differences in innate and adaptive immunity. Variations of sex hormone 
levels during aging and pregnancy or due to pharmacological intervention influence 
immune responses and can contribute to the sex disparities in oncology with lower 
cancer susceptibility in female populations. Emerging data also suggest female sex 
as a predictor of poor response to immune checkpoint inhibitors. Clinical trials are 
currently evaluating whether anti-estrogen or anti-androgen therapies could improve 
responses to such therapies.  
It remains to be determined whether these observed sex differences in 
immmunotherapy responses are possibly due to differences in the predominant 
immune escape mechanisms in tumours arising in men and women. An effect of sex 
hormones on disseminated tumor cells and the late relapse of hormone sensitive 
malignancies such as breast and prostate cancer, as well as on the microbiome needs 
to be investigated.   
 
 
 
